Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

(2019) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors

(2019) Suthee Rapisuwon et al.   Journal for ImmunoTherapy of Cancer

Hematologic Complications of Immune Checkpoint Inhibitors

(2019) Elizabeth J. Davis et al.   ONCOLOGIST

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

(2019) Deborah B Doroshow et al.   CLINICAL CANCER RESEARCH

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

(2018) Rituparna Das et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy

(2018) Yamin Sun et al.   JOURNAL OF IMMUNOTHERAPY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy

(2018) Sagun Parakh et al.   ONCOLOGIST

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy

(2018) Leo L. Wang et al.   JAMA Dermatology

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression

(2018) Nicholas Meti et al.   Journal of Oncology Practice

Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis

(2018) Fausto Petrelli et al.   EUROPEAN JOURNAL OF CANCER

Immune dysregulation in cancer patients developing immune-related adverse events

(2018) Shaheen Khan et al.   BRITISH JOURNAL OF CANCER

The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy

(2018) Arabella Young et al.   Cancer Immunology Research

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

(2018) Nicolas Delanoy et al.   Lancet Haematology

4A.03 Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy

(2017) A.R. Naqash et al.   Journal of Thoracic Oncology

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma

(2016) Teresa C. Longoria et al.   Expert Opinion on Drug Metabolism & Toxicology

Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab

(2016) Samer Tabchi et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade Expands Intratumoral Memory T Cells

(2016) A. Ribas et al.   Cancer Immunology Research

Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report

(2015) Sebastian Woźniak et al.   Oncology Research and Treatment

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)

(2009) Mojtaba Akhtari et al.   JOURNAL OF IMMUNOTHERAPY